Drug development in IBD: from novel target identification to early clinical trials

加药 临床试验 药物开发 医学 药物发现 功效 疾病 临床研究阶段 重症监护医学 药品 内科学 生物信息学 药理学 生物
作者
Silvio Danese,Claudio Fiocchi,Julían Panés
出处
期刊:Gut [BMJ]
卷期号:65 (8): 1233-1239 被引量:41
标识
DOI:10.1136/gutjnl-2016-311717
摘要

The two major forms of IBD, Crohn's disease (CD) and UC, are chronic inflammatory disorders, the pathogenesis of which involves a complex interplay of multiple factors.1 ,2 The introduction of biological agents has substantially expanded and improved the therapeutic options for IBD, but a large proportion of patients still do not respond or achieve remission in the short term or long term. Thus, there is still a considerable need to improve the treatment of IBD, and significant research efforts are underway to address this unmet need. During the last two decades, the period of time over which the biologics as well as other new drugs for IBD have entered the market, the number of therapies that have failed is remarkably high. This is significant, and understanding the reasons for such failure should lead to a better drug development process and pave the way for alternate and more efficient drug development strategies. Traditionally, the drug development process initially involves target discovery and selection, and then biological confirmation in cellular and animal models. This is followed by phase I testing in healthy volunteers to check for safety and pharmacokinetics, then phase II testing in patient volunteers to obtain preliminary safety, clinical efficacy and dosing data, and finally phase III clinical studies in patients to obtain a more comprehensive characterisation of the safety and efficacy profile of a drug. This traditional pathway of drug development has had relatively limited success in generating new forms of treatment for IBD. Results have been impacted by predictable high clinical response rates in the placebo groups, a lack of objective end points, trial design with arbitrary definitions of induction and maintenance phases and outcomes, and not taking into account key components of IBD pathogenesis.3 Moreover, a lack of strict criteria to ensure the presence …
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
一颗橙子应助长情访梦采纳,获得10
2秒前
wzg666完成签到,获得积分10
2秒前
胡萝卜完成签到 ,获得积分10
2秒前
4秒前
4秒前
6秒前
SHlby完成签到,获得积分10
8秒前
Lan完成签到 ,获得积分10
8秒前
9秒前
10秒前
飞鱼发布了新的文献求助10
10秒前
gu发布了新的文献求助10
11秒前
gshan04发布了新的文献求助10
11秒前
情怀应助SHlby采纳,获得10
11秒前
12秒前
科研通AI5应助胡萝卜采纳,获得10
12秒前
12秒前
gzslwddhjx完成签到,获得积分10
13秒前
稳重翠完成签到,获得积分10
13秒前
科研通AI2S应助lxy采纳,获得10
15秒前
不鸭完成签到 ,获得积分10
15秒前
16秒前
MOMOMO发布了新的文献求助10
16秒前
17秒前
Co完成签到 ,获得积分10
17秒前
稳重翠发布了新的文献求助10
18秒前
兔斯基完成签到,获得积分10
20秒前
李健应助MOMOMO采纳,获得10
25秒前
平常的过客完成签到,获得积分10
26秒前
Ava应助aaa采纳,获得10
26秒前
英姑应助袁美杰采纳,获得10
27秒前
29秒前
我是老大应助一步一步采纳,获得10
29秒前
别说话发布了新的文献求助20
31秒前
31秒前
小透明举报缥缈听芹求助涉嫌违规
32秒前
pwy完成签到,获得积分10
33秒前
劲秉应助liu15136110637采纳,获得30
35秒前
35秒前
KEcd完成签到 ,获得积分10
35秒前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2700
Ophthalmic Equipment Market 1500
Neuromuscular and Electrodiagnostic Medicine Board Review 1000
こんなに痛いのにどうして「なんでもない」と医者にいわれてしまうのでしょうか 510
いちばんやさしい生化学 500
Genre and Graduate-Level Research Writing 500
The First Nuclear Era: The Life and Times of a Technological Fixer 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3673627
求助须知:如何正确求助?哪些是违规求助? 3229144
关于积分的说明 9784412
捐赠科研通 2939740
什么是DOI,文献DOI怎么找? 1611281
邀请新用户注册赠送积分活动 760896
科研通“疑难数据库(出版商)”最低求助积分说明 736326